David M. Thomas

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

David M. Thomas, Robert M. Henshaw, Keith M. Skubitz et al. · The Lancet Oncology · 2010 · 711 citations

Medicine, Oncology, Surgery +12

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

Sant P. Chawla, Robert M. Henshaw, Leanne L. Seeger et al. · The Lancet Oncology · 2013 · 583 citations

Medicine, Oncology, Pediatrics +12

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

William D. Tap, Hans Gelderblom, Emanuela Palmerini et al. · The Lancet · 2019 · 474 citations · Full text

Medicine, Oncology, Pharmacology +5

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

Daniel Branstetter, Scott D. Nelson, J. Carlos Manivel et al. · Clinical Cancer Research · 2012 · 429 citations · Full text

Medicine, Oncology, Pharmacology +16

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

Marie Wong, Chelsea Mayoh, Loretta M. S. Lau et al. · Nature Medicine · 2020 · 404 citations · Full text

Life Sciences, Genetics, Oncology +14